

Zydus Cadila receives FDA approval for Metoprolol Succinate

26 March 2018 | News

The drug is used to treat chest pain (angina), heart failure and high blood pressure



Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Cadila has received the final approval from the USFDA to market Metoprolol Succinate Extended-Release Tablets USP in the strengths of 25 mg, 50 mg, 100 mg and 200 mg.

The drug is used to treat chest pain (angina), heart failure and high blood pressure.

Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has more than 185 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus aspires to be a research-based pharmaceutical company by 2020